# Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

> **NCT07400250** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Romiplostim N01

## Key facts

- **NCT ID:** NCT07400250
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400250, "Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07400250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*